Symbion Inc., the Salt Lake-based company dealing in cardiovascular support technology, had $5.7 million in sales in 1988, a 3.6 percent increase, which reduced the company's net loss 45 percent to $980,000.

Sales growth in 1988 was attributed to the MITROFLOW pericardial tissue valve, a new product acquired by Symbion last year. This product accounted for 27 percent of the company's sales.Company officials said implants of the company's cardiovascular support devices also improved in 1988. The J-7 total artificial heart was implanted in 57 patients during the year and 68 acute ventricular assist devices were used to support the natural heart of other patients.